Developmental and growth defects in mice with combined deficiency of CK2 catalytic genes

  • Esther Landesman-Bollag
  • Anna Belkina
  • Beth Hovey
  • Edward Connors
  • Charles Cox
  • David C. Seldin
Article

Abstract

The CK2 α and α′ catalytic gene products have overlapping biochemical activity, but in vivo, their functions are very different. Deletion of both alleles of CK2α leads to mid-gestational embryonic lethality, while deletion of both alleles of CK2α′ does not interfere with viability or development of embryos; however, adult CK2α′−/−males are infertile. To further elucidate developmental roles of CK2, and analyze functional overlap between the two catalytic genes, mice with combined knockouts were bred. Mice bearing any two CK2 catalytic alleles were phenotypically normal. However, inheritance of a single CK2α allele, without either CK2α′ allele, resulted in partial embryonic lethality. Such mice that survived through embryogenesis were smaller at birth than littermate controls, and weighed less throughout life. However, their cardiac function and lifespan were normal. Fibroblasts derived from CK2α+/−CK2α′−/− embryos grew poorly in culture. These experiments demonstrate that combined loss of one CK2α allele and both CK2α′ alleles leads to unique abnormalities of growth and development.

Keywords

Protein kinase CK2 Casein kinase II Homologous recombination Mouse embryonic fibroblast 

Notes

Acknowledgments

This study was supported by NCI R01 CA71796 (DCS). The authors acknowledge the assistance of Patrick Hogan with animal husbandry, Drs. Ravi Jasuja and GianlucaToraldo in the Metabolic Phenotyping Core for assistance with the NMR analysis, members of the Seldin laboratory, and Dr. Isabel Dominguez for helpful discussions.

References

  1. 1.
    Salvi M, Sarno S, Cesaro L, Nakamura H, Pinna LA (2009) Extraordinary pleiotropy of protein kinase CK2 revealed by weblogo phosphoproteome analysis. Biochim Biophys Acta 1793:847–859. doi: S0167-4889(09)00029-9 PubMedCrossRefGoogle Scholar
  2. 2.
    Meggio F, Pinna LA (2003) One-thousand-and-one substrates of protein kinase CK2? FASEB J 17:349–368PubMedCrossRefGoogle Scholar
  3. 3.
    Hanif IM, Shazib MA, Ahmad KA, Pervaiz S (2010) Casein kinase II: an attractive target for anti-cancer drug design. Int J Biochem Cell Biol 42:1602–1605. doi: S1357-2725(10)00207-4 PubMedCrossRefGoogle Scholar
  4. 4.
    Landesman-Bollag E, Romieu-Mourez R, Song DH, Sonenshein GE, Cardiff RD, Seldin DC (2001) Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 20:3247–3257PubMedCrossRefGoogle Scholar
  5. 5.
    Seldin DC, Leder P (1995) Casein kinase II alpha transgene-induced murine lymphoma: relation to theileriosis in cattle. Science 267:894–897 [see comments]PubMedCrossRefGoogle Scholar
  6. 6.
    Guerra B, Issinger OG (2008) Protein kinase CK2 in human diseases. Curr Med Chem 15:1870–1886PubMedCrossRefGoogle Scholar
  7. 7.
    Trembley JH, Chen Z, Unger G, Slaton J, Kren BT, Van Waes C, Ahmed K (2010) Emergence of protein kinase CK2 as a key target in cancer therapy. Biofactors 36:187–195. doi: 10.1002/biof.96 PubMedCrossRefGoogle Scholar
  8. 8.
    Sarno S, Pinna LA (2008) Protein kinase CK2 as a druggable target. Mol Biosyst 4:889–894PubMedCrossRefGoogle Scholar
  9. 9.
    Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O’Brien SE, Bliesath J, Omori M, Huser N, Ho C, Proffitt C, Schwaebe MK, Ryckman DM, Rice WG, Anderes K (2010) CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 70:10288–10298. doi: 10.1158/0008-5472.CAN-10-1893 PubMedCrossRefGoogle Scholar
  10. 10.
    Litchfield DW (2003) Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 369:1–15PubMedCrossRefGoogle Scholar
  11. 11.
    Duncan JS, Litchfield DW (2008) Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta 1784:33–47PubMedGoogle Scholar
  12. 12.
    Bodenbach L, Fauss J, Robitzki A, Krehan A, Lorenz P, Lozeman FJ, Pyerin W (1994) Recombinant human casein kinase II. A study with the complete set of subunits (alpha, alpha′ and beta), site-directed autophosphorylation mutants and a bicistronically expressed holoenzyme. Eur J Biochem 220:263–273PubMedCrossRefGoogle Scholar
  13. 13.
    Lou DY, Dominguez I, Toselli P, Landesman-Bollag E, O’Brien C, Seldin DC (2008) The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development. Mol Cell Biol 28:131–139PubMedCrossRefGoogle Scholar
  14. 14.
    Xu X, Toselli PA, Russell LD, Seldin DC (1999) Globozoospermia in mice lacking the casein kinase II alpha′ catalytic subunit. Nat Genet 23:118–121PubMedCrossRefGoogle Scholar
  15. 15.
    Seldin DC, Lou DY, Toselli P, Landesman-Bollag E, Dominguez I (2008) Gene targeting of CK2 catalytic subunits. Mol Cell Biochem 316:141–147PubMedCrossRefGoogle Scholar
  16. 16.
    Zhang C, Vilk G, Canton DA, Litchfield DW (2002) Phosphorylation regulates the stability of the regulatory CK2beta subunit. Oncogene 21:3754–3764PubMedCrossRefGoogle Scholar
  17. 17.
    Bolanos-Garcia VM, Fernandez-Recio J, Allende JE, Blundell TL (2006) Identifying interaction motifs in CK2beta—a ubiquitous kinase regulatory subunit. Trends Biochem Sci 31:654–661. doi: 10.1016/j.tibs.2006.10.005 PubMedCrossRefGoogle Scholar
  18. 18.
    Poletto G, Vilardell J, Marin O, Pagano MA, Cozza G, Sarno S, Falques A, Itarte E, Pinna LA, Meggio F (2008) The regulatory beta subunit of protein kinase CK2 contributes to the recognition of the substrate consensus sequence. A study with an eIF2 beta-derived peptide. Biochemistry 47:8317–8325. doi: 10.1021/bi800216d PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Esther Landesman-Bollag
    • 1
  • Anna Belkina
    • 1
  • Beth Hovey
    • 1
  • Edward Connors
    • 1
  • Charles Cox
    • 1
  • David C. Seldin
    • 1
  1. 1.Section of Hematology-Oncology, Department of MedicineBoston University School of Medicine and Boston Medical CenterBostonUSA

Personalised recommendations